Skip to main content
PMC home page
NPJ Vaccines logoLink to NPJ Vaccines
. 2020 Aug 5;5:73. doi: 10.1038/s41541-020-00220-4

A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice

Na Li 1,2, Zhe-Rui Zhang 1,2, Ya-Nan Zhang 1,2, Jing Liu 1,2, Cheng-Lin Deng 1, Pei-Yong Shi 3, Zhi-Ming Yuan 1, Han-Qing Ye 1,✉, Bo Zhang 1,4,✉
PMCID: PMC7406499  PMID: 32802412

Abstract

In our previous study, we have demonstrated in the context of WNV-ΔNS1 vaccine (a replication-defective West Nile virus (WNV) lacking NS1) that the NS1 trans-complementation system may offer a promising platform for the development of safe and efficient flavivirus vaccines only requiring one dose. Here, we produced high titer (107 IU/ml) replication-defective Japanese encephalitis virus (JEV) with NS1 deletion (JEV-ΔNS1) in the BHK-21 cell line stably expressing NS1 (BHKNS1) using the same strategy. JEV-ΔNS1 appeared safe with a remarkable genetic stability and high degrees of attenuation of in vivo neuroinvasiveness and neurovirulence. Meanwhile, it was demonstrated to be highly immunogenic in mice after a single dose, providing similar degrees of protection to SA14-14-2 vaccine (a most widely used live attenuated JEV vaccine), with healthy condition, undetectable viremia and gradually rising body weight. Importantly, we also found JEV-ΔNS1 induced robust cross-protective immune responses against the challenge of heterologous West Nile virus (WNV), another important member in the same JEV serocomplex, accounting for up to 80% survival rate following a single dose of immunization relative to mock-vaccinated mice. These results not only support the identification of the NS1-deleted flavivirus vaccines with a satisfied balance between safety and efficacy, but also demonstrate the potential of the JEV-ΔNS1 as an alternative vaccine candidate against both JEV and WNV challenge.

Subject terms: Vaccines, Live attenuated vaccines

Introduction

The Flavivirus genus of the Flaviviridae family consists of many important human arboviral pathogens responsible for encephalitis and hemorrhagic diseases, such as Japanese encephalitis virus (JEV), West Nile virus (WNV), Dengue virus (DENV), yellow fever virus (YFV), Zika virus (ZIKV), tick-borne encephalitis virus (TBEV), St. Louis encephalitis viruses (SLEV)1. Among these, JEV is the leading cause of viral encephalitis in the Asia-Pacific area, causing nearly 68,000 cases of Japanese encephalitis (JE) each year with the case fatality rates averaged around 30%. Even those who survive JE (~50%) often suffer from permanent neuronal disorders like cognitive, motor, and behavioral impairments2–5. No effective antiviral therapeutics against JEV is available.

JEV vaccines are therefore the only effective approach to prevent JEV infection. The currently used JEV vaccines are classified into four main types: inactivated mouse brain-derived vaccines, inactivated Vero cell-derived vaccines, live attenuated vaccines, and live chimeric vaccines6. The inactivated JEV vaccines derived either from mouse brain7 or Vero cells8,9 are relatively safer but require repeated doses to achieve adequate protection. For the live attenuated/chimeric vaccines, only one-dose administration is enough to induce protective immunity against JEV infection. SA14-14-2 and ChimeriVax-JE are the two most widely used live attenuated/chimeric vaccines. SA14-14-2, an attenuated strain derived from its wild-type (WT) JEV SA14 strain10,11, is generated through multiple passages of SA14 virus in primary hamster kidney (PHK) cells and in mouse brain/non-neural tissues plus repeated plaque purifications11. ChimeriVax-JE is a live recombinant vaccine by replacement of the genes encoding two structural proteins (preMemebrane (prM) and Envelope (E)) of a YFV vaccine strain (YFV-17D) with the corresponding genes of JEV SA14-14-2 strain12–14. This chimeric virus replicates like YFV-17D, but elicits specific immunity against the heterologous JEV surface antigens. Despite the excellent safety record of SA14-14-2, the concern about the potential virulence reversion remains10,15,16.

Recently, we generated a replication-defective WNV-ΔNS1 vaccine candidate with a deletion of viral nonstructural protein 1 (NS1) by utilizing the complementing cell line expressing NS1 protein. This WNV-ΔNS1 exhibited high levels of safety and efficacy in mice17. In this study, we extend the NS1 trans-complementary platform to the development of JEV vaccines. The high titers of replication-defective JEV-ΔNS1 viruses with an NS1 deletion were produced using the previously established BHK-21 stable cell line that expresses WT WNV NS1 protein (BHKNS1). Through in vitro blind passage in BHKNS1 cells and in vivo neuroinvasiveness and neurovirulence evaluation, we demonstrated that JEV-ΔNS1 was genetically stable and highly attenuated. Meanwhile, the results of vaccine efficacy showed that a single dose of JEV-ΔNS1 vaccine could protect C57BL/6 mice from a highly lethal challenge with WT JEV. Importantly, we also found JEV-ΔNS1 induced cross-protective immune responses against the challenge of heterologous WNV, another important member in the same JEV serocomplex, accounting for up to 80% survival rate following a single dose of immunization relative to mock-vaccinated mice. Our study indicates the potential of the JEV-ΔNS1 as an alternative safe and effective vaccine candidate against both JEV and WNV infection.

Results

Generation and characterization of JEV-ΔNS1 particles

Previously, we reported that WNV-ΔNS1 could replicate in VeroNS1 cell line efficiently17. In the present study, using the same method, we generated JEV-ΔNS1 particles through transfection of the transcribed JEV-ΔNS1 RNA into BHKNS1 cells stably expressing WNV NS1 protein (Fig. 1a). JEV-ΔNS1 particles replicated efficiently in BHKNS1 cells (Fig. 1b) with viral titers as high as 1 × 107 IU/ml at 96 h post infection (hpi) (Fig. 1c).

Fig. 1. High replication efficiency of JEV-ΔNS1 in BHKNS1 cell line.

Fig. 1

Open in a new tab

a Schematic diagram of the generation and replication of JEV-ΔNS1 particles in cells. JEV-ΔNS1 (with a deletion of the residues 4–298 in NS1 coding sequence) replicates efficiently in the BHK-21 cell line stably expressing WNV-NS1 protein (BHKNS1), while undergoes a single round of entry, release and viral RNA translation in the normal cells. b IFA detection of JEV-ΔNS1 and WNV-ΔNS1 in BHKNS1 cells post transfection. Equal amounts of JEV-ΔNS1 and WNV-ΔNS1 RNAs were transfected into BHKNS1 cells. IFA analysis using 4G2 monoclonal antibody was performed at the indicated time points. The length of the scale bar (displayed in a red line segment) represents 20 μm. c Comparison of growth kinetics of JEV-ΔNS1 and WNV-ΔNS1. BHKNS1 cells were infected with JEV-ΔNS1 and WNV-ΔNS1 virus at an MOI of 0.1. The supernatants were harvested at the indicated time points and viral titers were determined by IFA on BHKNS1 cells as described in “Methods”. Two independent experiments were performed in triplicate. Data represent the mean ± standard deviation (SD) of the triplicate measurements in a representative experiment. Statistical analysis was performed with unpaired t test and the asterisks denote statistical differences between the indicated groups. *p < 0.05; **p < 0.01; n.s. no statistical difference.

Then, we compared viral growth kinetics, viral proteins in virions and viral antigenicity between WT JEV (JEV-WT) and JEV-ΔNS1. (i) Similar viral growth curves were observed in BHKNS1 cells for these two viruses at a multiplicity of infection (MOI) of 0.1, with the highest titers of about 1 × 107 IU/ml at 96 hpi (Fig. 2a). (ii) After concentration and purification through PEG8000 precipitation and ultracentrifugation, the purified virions were subjected to western blotting analysis using envelope- (E) and capsid-specific (C) antibodies. Similar amount of viral proteins were detected in JEV-WT and JEV-ΔNS1 virion samples. (iii) The enzyme-linked immunosorbent assay (ELISA) was performed to detect the viral antigenicity using either JEV-WT or JEV-ΔNS1-coated 96-well plates. No significant differences in antigenicity between JEV-WT and JEV-ΔNS1 were observed as the same dilution of antisera against JEV-WT could equally recognize JEV-ΔNS1 antigen, suggesting that JEV-ΔNS1 virion remains antigenically intact (Fig. 2c).

Fig. 2. Characterization of JEV-ΔNS1.

Fig. 2

Open in a new tab

a Comparison of growth kinetics between WT JEV (JEV-WT) and JEV-ΔNS1 virus in BHKNS1 cells. BHKNS1 cells were infected with either JEV-WT or JEV-ΔNS1 virus at an MOI of 0.1. The supernatants were harvested at the indicated time points and viral titers were determined as described above. Data represent the mean ± standard deviation (SD) of the triplicate measurements in a representative experiment. Statistical analysis was performed with unpaired t test and the asterisks denote statistical differences between the indicated groups. **p < 0.01; n.s. no statistical difference. b Western blotting analysis of purified JEV-WT and JEV-ΔNS1 viral particles. Following concentration and purification through PEG8000 precipitation and ultracentrifugation, equal amounts of purified WT and ΔNS1 viruses were subjected to Western blotting analysis using the specific anti-E monoclonal antibody or anti-C polyclonal antibody. All blots derived from the same experiment and were processed in parallel. c ELISA for the detection of the antibodies against both JEV and JEV-ΔNS1. Two independent experiments were performed in triplicate. Data represent the mean ± standard deviation (SD) of the triplicate measurements in a representative experiment. Statistical analysis was performed with unpaired t test. n.s. no statistical difference.

Genetic stability of JEV-ΔNS1 particles

To investigate the stability of this vaccine candidate, three groups of JEV-ΔNS1 particles (Groups A, B and C) were passaged serially, independently, in BHKNS1 cells for 15 rounds (P0−P15). JEV-ΔNS1 viruses at P0 and P15 (P15-A, -B and -C) were used to infect BHKNS1 and the parental BHK-21 cells. All the infected cells were subjected to IFA and RT-PCR assay. As shown in Fig. 3a, the BHKNS1 cells infected with either group of P15 JEV-ΔNS1 produced robust IFA-positive signals, almost equivalent to those infected with P0 JEV-ΔNS1 or JEV-WT. In contrast, no IFA-positive signals were observed in all viruses except WT-infected BHK-21 cells. RT-PCR assay was carried out using the primer pair spanning the region from E to the C-terminus of NS2B that covers the complete NS1 coding sequence. The expected 2.7- and 1.8-kb RT-PCR products were detected in WT and JEV-ΔNS1 samples, respectively (Fig. 3b). Meanwhile, the sequencing result of NS1 coding region of P15 JEV-ΔNS1 also provided consistent evidence that the passaged virus still retained the same 295-residue deletion (residues 4-298) in NS1 protein (Fig. 3c). Overall, we confirmed that JEV-ΔNS1 virus is genetically stable and did not recombine with the WT NS1 sequences in the BHKNS1 cells.

Fig. 3. Stability of JEV-ΔNS1.

Fig. 3

Open in a new tab

a IFA analysis of JEV-ΔNS1 virus at different passages using 4G2 monoclonal antibody. The JEV-ΔNS1 virus generated through transfection of BHKNS1 cells with the transcribed JEV-ΔNS1 genomic RNA was designated as P0 virus. Three JEV-ΔNS1 virus stocks (A, B and C) were blind passaged independently for 15 rounds (P0−P15) in BHKNS1 cells. The viruses at P0 and P15 were used to infect BHKNS1 cells and naïve BHK-21 cells. JEV-WT was used as a positive control. The length of the scale bar (displayed in a red line segment) represents 20 μm. b RT-PCR analysis of the expression of NS1 gene in BHKNS1 cells infected with P0 or P15 JEV-ΔNS1 viruses. The uncropped and unprocessed gel including markers was displayed in Supplementary Fig. 2. c Sequence chromatograms of RT-PCR products containing NS1 fragment amplified from P15 JEV-ΔNS1 virus.

Assessment of neuroinvasiveness and neurovirulence of JEV-ΔNS1 in mice

To further evaluate the biosafety of JEV-ΔNS1 as vaccine candidate, we compared the neuroinvasiveness of the WT and JEV-ΔNS1 viruses in mice. Groups of 4-week-old C57BL/6 mice were inoculated intraperitoneally (i.p.) with 105, 106 and 107 IU of WT JEV or 107 IU of JEV-ΔNS1; the mortality of the infected mice was monitored for 3 weeks. In both WT virus-infected groups, almost all the mice showed serious diseases, such as ruffled fur and weight loss since day 5 post infection (Fig. 4b), and only one mouse in each WT group survived at the end of the observation period (Fig. 4a). In JEV-ΔNS1 virus-infected group, however, all the mice survived (Fig. 4a) with steadily increasing body weight and no signs of illness (Fig. 4b). We also compared the neurovirulence of the WT and JEV-ΔNS1 viruses in mice. Three-week-old ICR mice were inoculated intracranially (i.c.) with 10 IU of WT or 7.5 × 106 IU of JEV-ΔNS1. As shown in Fig. 4c, d, all the WT-inoculated mice died within 10 days (Fig. 4c) and displayed symptoms (ruffled fur, hunched back, paralysis) from day 3 post infection (Fig. 4d). In spite of inoculation with 100,000-fold higher dosage of JEV-ΔNS1 viruses, all the mice survived without neurological symptoms (Fig. 4c, d). Collectively, these results indicate that the JEV-ΔNS1 virus is highly safe in mice.

Fig. 4. JEV-ΔNS1 is highly safe in mice.

Fig. 4

Open in a new tab

a, b Neuroinvasiveness tests for WT and JEV-ΔNS1 viruses in mice. Four-week-old C57BL/6 female mice (n = 5 for each group) were i.p. inoculated with 106 and 107 IU of WT JEV or 107 IU of JEV-ΔNS1. The mortality (a) and weight loss (b) were monitored for 21 days. c, d Neurovirulence tests for WT and JEV-ΔNS1 viruses in mice. Three-week-old ICR female mice (n = 5 for each group) were i.c. inoculated with 10 IU of WT JEV or 7.5 × 106 IU of JEV-ΔNS1. The mortality (c) and weight loss (d) were monitored for 21 days. Kaplan−Meier survival curves were analyzed by the log-rank test and the asterisks denote statistical differences between the indicated groups. *p < 0.05; ***p < 0.001. Two independent experiments were performed, and data from one experiment are presented.

Protective efficacy of JEV-ΔNS1 against virulent JEV challenge in C57BL/6 mice

To evaluate the potency of JEV-ΔNS1 as a vaccine candidate, we firstly examined the antibody response induced by JEV-ΔNS1 in immunocompetent C57BL/6 mice. Four-week-old C57BL/6 mice (n = 10 for each group) were i.p. immunized three times at 3-week intervals. Each time the mice were inoculated with 1 × 107 IU of JEV-ΔNS1 (Fig. 5a). As shown in Fig. 5b, JEV-ΔNS1 immunization induced robust antibody titers assayed by ELISA on day 14 (1:440) and day 21 (1:1040), and the following boosters further elevated the antibody titers to 1:43,520 on day 56 and afterwards (Fig. 5b). In agreement with the ELISA titers, neutralizing antibody titers reached 1:68 after the third immunization despite lower than the limit of our detection after the primary immunization (Fig. 5c). The results demonstrate that JEV-ΔNS1 could induce a robust antibody response.

Fig. 5. Protection of JEV-ΔNS1 in mice against JEV challenge.

Fig. 5

Open in a new tab

a Schematic diagram of animal experiment design and schedule. Four-week-old C57BL/6 female mice (n = 10 for each group) were i.p. immunized three times at 3-week intervals with 1 × 107 IU of JEV-ΔNS1. At the indicated time points, the sera harvested from immunized mice were subjected to ELISA (b) and PRNT50 (c) to determine the IgG antibody and neutralizing antibody titers against JEV, respectively. ND not detected. d Viremia levels in WT JEV challenged mice. All mice in each group were i.p. injected with 3 × 107 PFU of WT JEV at 23 days after the third immunization. The serum viremia levels were quantified by plaque assay in BHK-21 cells on days 1 and 2 post challenge. Mice without any treatment (mock) were used as a negative control. The dashed lines in panels (b−d) represent the limits of detection. Data represent the mean ± standard deviation of ten mice at each time point in each group. Statistical analysis was performed with one-way ANOVA and the asterisks denote statistical differences between the indicated time points in panels (b) and (c) or different groups in panel (d). ***p < 0.001; ****p < 0.0001; n.s. no statistical differences.

To determine the protective efficacy of JEV-ΔNS1 virus against WT JEV, all the mice immunized with either phosphate-buffered saline (PBS) or JEV-ΔNS1 were i.p. challenged with 3 × 107 PFU of WT JEV 23 days after the third immunization (Fig. 5a). As expected, all the JEV-ΔNS1-immunized mice remained healthy without any signs of illness during the observation period of 15 days. In contrast, the PBS-immunized mice started to show signs of disease (such as ruffled fur and paralysis) from day 6 post challenge. But none of them succumbed to infection, which may attribute to, as previously reported18–20, the age-dependent resistance to JEV infection. The viremia levels were measured on days 1 and 2 post challenge. All the mice immunized with PBS developed high levels of viremia, with the average viremia titers of about 105 PFU/ml and 103 PFU/ml on days 1 and 2 post challenge, respectively, in contrast to undetectable viremia in the JEV-ΔNS1-immunized group (Fig. 5d). Taken together, these results show that JEV-ΔNS1 could protect mice from virulent challenge of WT JEV.

Protective efficacy of single immunization with JEV-ΔNS1 in C57BL/6 mice

To further explore whether a single vaccination with JEV-ΔNS1 was sufficient to elicit protective immunity against JEV, C57BL/6 mice were immunized only once with JEV-ΔNS1 prior to challenge. We also compared the vaccine efficacy of JEV-ΔNS1 with the commonly used JEV live attenuated vaccine, SA14-14-2 (the JEV live attenuated vaccine) at the same dosage. At the same time, the commercial YFV-17D vaccine (the YFV live attenuated vaccine) was used as a negative control. Sera collected on day 14 were subjected to ELISA (Fig. 6a). As shown in Fig. 6b, on day 14, the average IgG titers against JEV were 1:1200 and 1:11,200 for the groups treated with JEV-ΔNS1 and SA14-14-2, respectively; and only weak IgG titers were detected in one mouse of the YFV-17D immunized group. At 16 days post immunization, all mice, including PBS-vaccinated ones, were i.p. challenged with 3 × 107 PFU of WT JEV. Mice were then monitored daily for weight loss and visible signs of disease. All mice received either JEV-ΔNS1 or SA14-14-2 vaccine remained healthy, with undetectable viremia (Fig. 6c) and gradually rising body weight (Fig. 6d), while the PBS- and YFV-17D-vaccinated mice exhibited high levels of viremia with the average viremia titers of >105 and >103 PFU/ml on days 1 and 2 post challenge, respectively (Fig. 6c), and started to display disease symptoms like weight loss from day 5 after the infection (Fig. 7d) (though recovered gradually from day 7). Also, the IgG antibody titers against JEV were measured at 0 and 14 days post challenge. The titers increased significantly in mice immunized with different vaccines, relative to their counterparts prior to challenge (Fig. 6e). Altogether, our results suggest that a single dose of JEV-ΔNS1 vaccine was able to confer efficient protection against JEV, which was equivalent to the licensed JEV vaccine.

Fig. 6. Protective efficacy of one-shot immunization with JEV-ΔNS1 in C57BL/6 mice.

Fig. 6

Open in a new tab

a Schematic diagram of animal experiment design and schedule. Four-week-old female C57BL/6 mice (n = 6 for each group) were i.p. immunized once with 1.4 × 107 IU of JEV-ΔNS1 and SA14-14-2 or 6 × 105 IU of YFV-17D. At 14 days after the immunization, the sera harvested from immunized mice was subjected to ELISA to detect the IgG antibody titers against JEV (b). ND not detected. c, d Viremia levels and weight changes in WT JEV challenged mice. All mice were i.p. injected with 3 × 107 PFU of WT JEV at 16 days post immunization and monitored for viremia (c), weight loss (d), and IgG post-challenge titers (e). The dashed lines in panels (b, c and e) represent the limits of detection. Data represent the mean ± standard deviation of six mice at each time point in each group. Statistical analysis was performed with unpaired t test and the asterisks denote statistical differences between the indicated groups. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s. no statistical differences. Two independent experiments were performed, and data from one experiment are presented.

Fig. 7. Cross-protection against WNV with one-shot low-dose immunization of JEV-ΔNS1.

Fig. 7

Open in a new tab

a Schematic diagram of animal experiment design and schedule. b, c ELISA for the detection of antibody titers. Four-week-old female C57BL/6 mice (n = 10 for PBS- and 3 × 107 IU of JEV-ΔNS1-immunized groups; n = 5 for the other groups) were i.p. immunized once with different dosages of JEV-ΔNS1 (3 × 104, 3 × 105, 3 × 106, or 3 × 107 IU). On days 14 and 28, the sera were collected for the measurement of IgG antibody titers against JEV (b) and WNV (c), respectively. All mice were i.p. injected with 3 × 107 PFU of WT WNV at 30 days post immunization. The mortality (d) and weight loss (e) were monitored daily. The viremia (f), viral load in various organs (g), IgG post challenge titers (h) and neutralizing antibody titers (i) against WNV at the indicated times post challenge were assayed as described in “Methods”. The dashed lines in panels (b, c, f−i) represent the limits of detection. Data represent the mean ± standard deviation (SD) of five mice at each time point in each group. Statistical analysis was performed with unpaired t test and Kaplan−Meier survival curves were analyzed by the log-rank test. The asterisks denote statistical differences between the indicated groups. *p < 0.05; **p < 0.01; ****p < 0.0001; n.s. no statistical differences.

Cross-protection against WNV with one-shot low-dose immunization of JEV-ΔNS1

To further exploit the vaccine potential of JEV-ΔNS1, heterologous protection against WNV was investigated. The C57BL/6 mice were vaccinated once with four dosages (3 × 104, 3 × 105, 3 × 106 and 3 × 107 IU) of JEV-ΔNS1, respectively. ELISA assays were performed on days 14 and 28 post immunization for the titration of JEV- and WNV-reactive antibodies in mouse sera (Fig. 7a). It showed that JEV-ΔNS1 vaccination induced high levels IgG antibodies against both JEV and WNV in a dose-dependent manner. Specifically, the average anti-JEV titers were 1:50, 1:500, 1:2000, 1:2240 and the average anti-WNV titers were undetectable, 1:312, 1:650 and 1:1280 in the sera of mice immunized with 3 × 104, 3 × 105, 3 × 106 and 3 × 107 IU of JEV-ΔNS1 vaccines at 28 days post vaccination, respectively (Fig. 7b, c). At 30 days post immunization, all mice were i.p. challenged with 3 × 107 PFU of WT WNV and observed daily for weight change and disease. Consistent with the cross-reactive IgG response to WNV, immunization of JEV-ΔNS1 also provided a dose-dependent protection against virulent WNV challenge. Except the lowest dosage (3 × 104 IU), vaccination with 3 × 105, 3 × 106 and 3 × 107 IU of JEV-ΔNS1 enhanced the survival rate to 40%, 60% and 80%, respectively, in comparison with the PBS-vaccinated group (Fig. 7d). In addition, these three groups of mice exhibited increasing body weight (Fig. 7e) during the whole observation period, and low levels of viremia at 2 days post challenge (Fig. 7f). On day 4 post challenge, the viral loads in a variety of organs of mice immunized with PBS (Fig. 7g) were also detected. In contrast to high levels of viral loads in all the tested organs of PBS-vaccinated mice, the JEV-ΔNS1-vaccinated mice only had a minor level of viruses in the brain (Fig. 7g). The IgG antibody and neutralizing antibody titers against WNV were also increased in mice immunized with different dosages of JEV-ΔNS1 relative to the counterparts prior to challenge (Fig. 7h, i). Overall, our results illustrated that JEV-ΔNS1 could protect mice from a highly lethal challenge of WNV.

Discussion

Currently, there have been various inactivated and live attenuated/chimeric JEV vaccines available7,12,15, but the concerns about the efficacy or safety greatly limit their wide utilization. Flavivirus NS1 is a highly conserved glycoprotein with multiple functions in different forms21. Intracellular NS1 dimer is associated with the viral replication complex on the surface of the endoplasmic reticulum membrane and plays an essential role in viral RNA replication through modulating different viral and host factors22–25. The replication defect caused by NS1 mutations could be restored in trans by ectopic expression of homologous or even heterologous NS1 protein. Secreted and cell surfaced-associated NS1 are highly immunogenic and contribute to viral pathogenesis and immune evasion26–30. Antibodies against NS1 have been demonstrated to be protective against flavivirus infection. NS1-based subunit and DNA vaccines against JEV, DENV, YFV and ZIKV are developed at different stages21,31. In this study, we develop the replication-defective vaccine candidate, JEV-ΔNS1, using the NS1 trans-complementary platform we previously established17. It shows that JEV-ΔNS1 combines the safety and efficacy advantages of inactivated and live attenuated/recombinant vaccines: (i) It efficiently replicates in NS1 trans-complementing cell line but not in normal cells (Figs. 1 and 2a, b), and displays satisfied safety with good genetic stability (Fig. 3) and no apparent neurovirulence and neuroinvasiveness phenotypes in mice inoculated with high doses of JEV-ΔNS1 (Fig. 4); (ii) it maintains intact surface antigens that could not only be equally recognized by WT JEV antisera in ELISA assay (Fig. 2c), but also stimulate immune responses for efficient protection of mice against WT JEV challenge (Fig. 6).

In the vaccine efficacy assay, a commercial live attenuated JEV vaccine, SA14-14-2, was also used as a positive control. Vaccination with equal infectious titers of JEV-ΔNS1 gave similar degrees of protection to that of SA14-14-2, with healthy condition, undetectable viremia (Fig. 6c) and gradually rising body weight (Fig. 6d), although induced ~10-fold lower IgG antibody titers than vaccination with SA14-14-2. The differences in antibody titers between these two vaccines may result from their different replication capabilities: unlike SA14-14-2 continuously replicating in vivo, JEV-ΔNS1 only undergoes a single round of entry, release and viral antigens translation due to the NS1 deletion-caused complete block of viral genome replication.

Remarkably, a robust heterologous protection against WNV was observed in mice immunized with one-shot of JEV-ΔNS1 (Fig. 7). Both JEV and WNV belong to the antigenically related JEV serocomplex of flaviviruses. WNV is commonly found in Africa, Europe, the Middle East, North America and West Asia32–34. Recently, there have been reported clinically IgM-positive cases and isolated WNV from mosquito pools in China where JEV is endemic34,35. For the viruses without vaccines like WNV, cross-protective vaccination represents a promising approach against antigenically related viruses36–38. The cross-reactivity and protection of JEV vaccines against the closely related WNV have been investigated by different groups1,39–41. It showed that the natural infection of JEV or the vaccination of live attenuated/chimeric vaccines (SA14-2-8/ChimeriVax-JE) usually afforded strong cross-protective immunity against WNV infection38–41, with an exception that vaccination of SA14-14-2 failed to induce WNV-reactive antibodies in human recipients36,42. In comparison, immunization with inactivated vaccines provided robust heterologous protection against lethal WNV challenge only when co-delivery with YFV-17D vaccine43 or administration with Advax adjuvant44,45. It may attribute to the broad-based immune arsenal recruited by the adjuvants45. In the current study, JEV-ΔNS1 vaccine functions like live or attenuated/chimeric viruses, providing robust cross-protection of immunized mice against lethal WNV challenge with one-shot administration. Due to the sensitivity of PRNT assay we used here, the neutralizing antibody was not detectable after one-dose immunization despite the robust induction of antibody titers observed in ELISA assay. Nevertheless, we do believe that neutralizing antibody could be induced. As shown in Fig. 5c, after two rounds of vaccination, the neutralizing antibodies could be detected. Consistently, JEV-ΔNS1 vaccination induced strong cross-reactive antibody against WNV with an average titer 1:1280 at the highest dosage, only slightly less than the titer of anti-JEV antibody (1:2240) (Fig. 7).

In brief, our results showed that JEV-ΔNS1 is a safe and effective vaccine candidate, providing strong dual protection against both JEV and WNV challenge, and serving as a powerful tool to prevent both viruses infection, especially in their co-circulating areas.

Methods

Cells, viruses and antibodies

BHK-21 cells (ATCC® CCL-10™) were grown inDulbecco’s modified Eagle’s medium (DMEM) (Gibco) containing 10% heat-inactivated fetal bovine serum (Gibco), 100 units/ml of penicillin, 100 µg/ml of streptomycin in 5% CO2 at 37 °C. The stable BHK-21 cell line expressing NS1 protein (named as BHKNS1) was established following the same protocol as described previously for the generation of VeroNS117,46. BHKNS1 cells were grown in DMEM as described above plus 0.8 µg/ml of puromycin (Invitrogen) in 5% CO2 at 37 °C. It is worthwhile noting that Vero cells are more widely accepted for vaccine study. Unfortunately, we lost our Vero cell line stably expressing WNV NS1 protein (VeroNS1) used in our previous study17. Alternatively, we conducted our study using another pre-established BHKNS1 cell line. The selection of a new VeroNS1 cell line is also undergoing for our future study. The reason we did not use JEV NS1 for packaging cells is that we had already obtained WNV NS1 expressing cell line and found that WNV NS1 could trans-complement JEV-ΔNS1 efficiently. Additionally, we hypothesize that NS1 from different virus may further decrease the possibility of recombination to produce WT virus. Recombinant WT JEV and WT WNV were generated by electroporation of BHK-21 cells with the transcribed viral genomic RNA from the linearized infectious cDNA clone of SA-1447 and strain 3356 from New York City48,49, respectively. JEV-ΔNS1 vector was constructed in the context of WT JEV cDNA clone following the same method as described previously for the generation of WNV-ΔNS117,46, and the resultant replication-defective JEV-ΔNS1 and WNV-ΔNS1 viruses were obtained by lipofection (DMRIE-C Reagent, Invitrogen) of BHKNS1 cells with the transcribed viral genomic RNA from the linearized infectious cDNA clone of JEV-ΔNS1 and WNV-ΔNS1, respectively. The supernatants of transfected cells were harvested at 96 h post transfection (hpt) and frozen aliquots at −80 °C.

Monoclonal antibody 4G2 against the flavivirus envelope protein was kindly provided by Cheng-Feng Qin (Beijing Institute of Microbiology and Epidemiology, Beijing, China). Anti-JEV capsid polyclonal antibody was purchased from Abcam (China). Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG and horseradish peroxidase (HRP)-conjugated goat anti-mouse/rabbit IgG secondary antibodies were purchased from Proteintech (China).

Mice

Four-week-old C57BL/6 mice were used for virus neuroinvasiveness, immunization and challenge studies, and 3-week-old ICR mice were used to test the neurovirulence of JEV-ΔNS1. All mice infection experiments related to JEV were performed at an animal biosafety level 2 (ABSL-2) facility in Wuhan Institute of Virology under a protocol approved by the Laboratory Animal Ethics Committee of Wuhan Institute of Virology, CAS (Permit number: WIVA26201902). All mice infection experiments related to WNV were performed at an animal biosafety level 3 (ABSL-3) facility in Wuhan Institute of Virology under a protocol approved by the Laboratory Animal Ethics Committee of Wuhan Institute of Virology, CAS (Permit number: WIVA26201801).

Vaccine strains

SA14-14-2 (the JEV live attenuated vaccine strain) was kindly provided by Prof. Geng-Fu Xiao (Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China). YFV-17D (the YFV live attenuated vaccine) was purchased from Beijing Tiantan Biological Products Co., Ltd.

Viral titers quantification with immunofluorescence assay (IFA)

BHKNS1 cells seeded on coverslips in 12-well plates (2 × 105 BHKNS1 cells per well) were infected with tenfold dilutions of JEV, JEV-ΔNS1 or WNV-ΔNS1 for 1 h at 37 °C before being overlaid with 2% methylcellulose. At 48 hpi, the infected cells were washed three times with PBS, followed by fixation by cold 5% acetone in methanol for 15 min at room temperature. Then, the fixed cells were stained with 4G2 antibody for 1 h at room temperature, washed three times with PBS, and incubated with FITC-conjugated goat anti-mouse IgG polyclonal secondary antibody. After three washes with PBS, the coverslips were mounted on glass slides with 90% glycerol. Images were captured under a fluorescence microscope (Nikon Eclipse TE2000). The infectious titer of viruses was calculated as IU per milliliter.

Virus growth kinetics

The virus growth kinetics of JEV, JEV-ΔNS1 and WNV-ΔNS1 were performed in BHKNS1 cells. The cells were infected with viruses at a density of 2 × 105 cells/well in 12-well plates (MOI = 0.1). At the indicated time points post infection, the supernatants were collected and subjected to viral titer quantification as described above.

Concentration and purification of viral particles

The concentration and purification of WT JEV or JEV-ΔNS1 viral particles were carried out as described previously except that the supernatants were collected at 96 hpi17. Briefly, the supernatants reclaimed from infected BHKNS1 cells were subjected to sequential centrifugation to obtain the clarified stocks. Following incubation overnight at 4 °C with PBS containing 8% (wt/vol) PEG8000 (Sigma), the samples were centrifugated at 4 °C for 50 min at 10,500 × g. After gently resuspended with PBS, the pellets were subjected to ultracentrifugation at 4 °C for 1.5 h at 105,000 × g with a 24% sucrose cushion, using a SW41 rotor in an Optima MAX-XP ultracentrifuge (Beckman). The pellets were finally resuspended in 50 μl of PBS.

Blind passage of JEV-ΔNS1 in BHKNS1 cells

The JEV-ΔNS1 derived from BHKNS1 cells transfected with in vitro transcribed JEV-ΔNS1 genomic RNA was designated as P0 virus for the following blind passage. Three independent passages (A, B and C) were performed. Initially, BHKNS1 cells growing in cell culture dish (35 mm) were infected with JEV-ΔNS1 (P0) at an MOI of 0.01, and at 3 days post infection, the supernatants were collected as P1. All the subsequent passages were carried out by repeatedly infecting naïve BHKNS1 cells in a 35 mm culture dish with 10 μl of culture medium from the previous passage and incubating for 3−5 days.

Gel electrophoresis

After being heated at 95 °C for 10 min in SDS sample buffer containing β-mercaptoethanol, the denatured virion samples were subjected to electrophoresis on a 15% SDS-PAGE. The gel was then subjected to western blotting analysis as described previously46. All blots derived from the same experiment and were processed in parallel, the blots we presented in Fig. 2b were cropped into proper view and the raw data including molecular weight markers were displayed in Supplementary Fig. 1.

Mouse neuroinvasiveness and neurovirulence tests

For neuroinvasiveness test, 4-week-old female C57BL/6 mice were infected i.p. with 106 and 107 IU of WT JEV or 107 IU of JEV-ΔNS1. For neurovirulence test, 3-week-old female ICR mice were infected i.c. with 10 IU of WT JEV or 7.5 × 106 IU of JEV-ΔNS1. The animals were all observed for survival and body weight changes for 21 days.

Immunity and challenge studies

Four-week-old female C57BL/6 mice were i.p. immunized three times at 3-week intervals with 1 × 107 IU of JEV-ΔNS1; the mice immunized with PBS were used as a negative control. At 23 days after the third vaccination, all the mice were i.p. challenged with 3 × 107 PFU of WT JEV and monitored for survival and physical sign for 15 days. For one-shot immunization, three cohorts of mice were i.p. immunized once with 1.4 × 107 IU of JEV-ΔNS1 and SA14-14-2 and 6 × 105 IU of YFV-17D, respectively, followed by i.p. challenge with 3 × 107 PFU of WT JEV at 16 days post immunization. The weight loss and survival were monitored for 15 days. For heterologous protection assay, the mice were i.p. immunized once with 3 × 104, 3 × 105, 3 × 106 or 3 × 107 IU of JEV-ΔNS1, then i.p. challenged with 3 × 107 PFU of WT WNV at 30 days post immunization and monitored for weight loss and survival for 21 days. Viremia was quantified at 1 day and 2 days post challenge by plaque assay in BHK-21 cells as described previously48,50, and the limit of detection was 102 PFU/ml. The IgG antibody titers were also quantified on days 14 and 28 after challenge.

Organ virus titers

Organs from half of PBS and the highest JEV-ΔNS1 vaccine dosage (3 × 107 IU) treated mice were removed, homogenized, and measured for viral loads on day 4 post challenge by plaque assay in BHK-21 cells as described above.

Enzyme-linked immunosorbent assay (ELISA)

ELISA was used to measure antigenicity of JEV-ΔNS1 and JEV-specific IgG antibody levels of vaccinated mice as described previously17. The purified viral particles (WT JEV or JEV-ΔNS1) dissolved in lysis buffer (10% glycerin and 1% Triton X-100 in deionized water) were diluted with coating buffer (0.085 M sodium bicarbonate and 0.015 M sodium carbonate, pH9.5) to 100 ng/ml. One hundred microliters of diluted volumes (10 ng) were added to each well in a 96-well plate. The coated 96-well plates were then blocked with PBS containing 5% skimmed milk. The fourfold serial dilutions (starting at a 1:50 dilution) of heat-inactivated sera from vaccinated mice were added to the coated plates, followed by incubation with the HRP-conjugated goat anti-mouse IgG secondary antibody, and visualized using a two-component 3,3′,5,5′-tetramethylbenzidine (TMB) color development kit (Beyotime Biotechnology). After the addition of 1 M H2SO4 stop solution, the optical density at 450 nm was measured using a multimode microplate reader (Varioskan Flash; Thermo Fisher) according to the manufacturer’s instruction. The IgG antibody titers were defined as the highest dilution of sera giving an optical density twice that of the nonimmune sera.

Plaque reduction neutralization test (PRNT)

The neutralizing activities of sera were assayed by PRNT as described previously17,48,51. Briefly, serial twofold dilutions of heat-inactivated serum samples (starting at a 1:20 dilution) were preincubated with WT JEV for 1 h at 37 °C and then added to 12-well plates pre-seeded with BHK-21 cells. The mixture was then removed followed by virus quantification by plaque assay. The neutralizing antibody titers (PRNT50) were calculated as the highest serial dilutions producing a 50% reduction in viral plaque numbers compared with the control.

Statistical analysis

The unpaired t test or one-way ANOVA was used to determine whether there were significant differences (p < 0.05) in all experiments. Kaplan−Meier survival curves were analyzed by the log-rank test. The statistical analyses were performed using nonparametric test in GraphPad Prism software 5.0.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Supplementary information

Supplementary Information (525.3KB, pdf)
Reporting Summary (2MB, pdf)

Acknowledgements

We are grateful to Center for Animal Experiment staff (Xue-fang An, Fan Zhang, He Zhao and Li Li) and BSL-3 laboratory (Hao Tang) at Wuhan Institute of Virology and Wuhan Key Laboratory of Special Pathogens and Biosafety for their helpful supports during the course of the work. This work was supported by the National Key Research and Development Program of China (2018YFA0507201). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

B.Z. conceived and led this study. B.Z., H.-Q.Y. and N.L. drafted the manuscript. N.L., Z.-R.Z., Y.-N.Z., J.L. and C.-L.D. performed the experiments. P.-Y.S. and Z.-M.Y. provided the materials for the study.

Data availability

All data to understand and assess the conclusions of this study are available in this published article. The raw data that support the findings of this study are available from the corresponding author upon reasonable request.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Han-Qing Ye, Email: yehq@wh.iov.cn.

Bo Zhang, Email: zhangbo@wh.iov.cn.

Supplementary information

Supplementary information is available for this paper at 10.1038/s41541-020-00220-4.

References

  • 1.Li SH, et al. Cross protection against lethal West Nile virus challenge in mice immunized with recombinant E protein domain III of Japanese encephalitis virus. Immunol. Lett. 2011;138:156–160. doi: 10.1016/j.imlet.2011.04.003. [DOI] [PubMed] [Google Scholar]
  • 2.Misra UK, Kalita J. Movement disorders in Japanese encephalitis. J. Neurol. 1997;244:299–303. doi: 10.1007/s004150050090. [DOI] [PubMed] [Google Scholar]
  • 3.Rashmi Kumar PT, Singh S, Bannerji G. Clinical features in children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh, India. Clin. Infect. Dis. 2006;43:123–131. doi: 10.1086/505121. [DOI] [PubMed] [Google Scholar]
  • 4.Martina BE, et al. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine. 2008;26:153–157. doi: 10.1016/j.vaccine.2007.10.055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Murgod UA, Muthane UB, Ravi V, Radhesh S, Desai A. Persistent movement disorders following Japanese encephalitis. Neurology. 2001;57:2313–2315. doi: 10.1212/wnl.57.12.2313. [DOI] [PubMed] [Google Scholar]
  • 6.World Health Organization. Japanese encephalitis. https://www.who.int/news-room/fact-sheets/detail/japanese-encephalitis (2019).
  • 7.Lobigs M, et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J. Gen. Virol. 2010;91:1407–1417. doi: 10.1099/vir.0.019190-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Appaiahgari MB, Vrati S. Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine. 2004;22:3669–3675. doi: 10.1016/j.vaccine.2004.03.024. [DOI] [PubMed] [Google Scholar]
  • 9.Li J, et al. Characterization of immune responses induced by inactivated, live attenuated and DNA vaccines against Japanese encephalitis virus in mice. Vaccine. 2013;31:4136–4142. doi: 10.1016/j.vaccine.2013.06.099. [DOI] [PubMed] [Google Scholar]
  • 10.Yun SI, et al. Comparison of the live-attenuated Japanese encephalitis vaccine SA14-14-2 strain with its pre-attenuated virulent parent SA14 strain: similarities and differences in vitro and in vivo. J. Gen. Virol. 2016;97:2575–2591. doi: 10.1099/jgv.0.000574. [DOI] [PubMed] [Google Scholar]
  • 11.Yu Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine. 2010;28:3635–3641. doi: 10.1016/j.vaccine.2010.02.105. [DOI] [PubMed] [Google Scholar]
  • 12.Monath TP, et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 2000;74:1742–1751. doi: 10.1128/jvi.74.4.1742-1751.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Guirakhoo F, et al. Immunogenicity, genetic stability and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (Chimerivax™-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999;257:363–372. doi: 10.1006/viro.1999.9695. [DOI] [PubMed] [Google Scholar]
  • 14.Chambers TJ, Nestorowicz A, Mason PW, Eckels KH, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 1999;73:3095–3101. doi: 10.1128/jvi.73.4.3095-3101.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Eckels KH, Yu YX, Dubois DR, Marchette NJ, Trent DW. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine. 1988;6:513–518. doi: 10.1016/0264-410x(88)90103-x. [DOI] [PubMed] [Google Scholar]
  • 16.Yang D, et al. Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2. Vaccine. 2014;32:2675–2681. doi: 10.1016/j.vaccine.2014.03.074. [DOI] [PubMed] [Google Scholar]
  • 17.Li N, et al. Replication-defective West Nile virus with NS1 deletion as a new vaccine platform for flavivirus. J. Virol. 2019;93:e00720–00719. doi: 10.1128/JVI.00720-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Koning LJ, van der Meer C. The cause of death of Palaemonetes varians (Leach, 1814) treated with cholinesterase inhibitors. Comp. Biochem. Physiol. C. 1975;51:73–77. doi: 10.1016/0306-4492(75)90041-6. [DOI] [PubMed] [Google Scholar]
  • 19.Kimura T, et al. Characterization of Japanese encephalitis virus infection in an immortalized mesencephalic cell line, CSM14.1. Microbiol. Immunol. 2013;57:723–731. doi: 10.1111/1348-0421.12085. [DOI] [PubMed] [Google Scholar]
  • 20.Jain N, et al. CD8 T cells protect adult naive mice from JEV-induced morbidity via lytic function. PLoS Negl. Trop. Dis. 2017;11:e0005329. doi: 10.1371/journal.pntd.0005329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Rastogi M, Sharma N, Singh SK. Flavivirus NS1: a multifaceted enigmatic viral protein. Virol. J. 2016;13:131. doi: 10.1186/s12985-016-0590-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Khromykh AA, Sedlak PL, Guyatt KJ, Hall RA, Westaway EG. Efficient trans-complementation of the flavivirus kunjin NS5 protein but not of the NS1 protein requires its coexpression with other components of the viral replicase. J. Virol. 1999;73:10272–10280. doi: 10.1128/jvi.73.12.10272-10280.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lindenbach BD, Rice CM. trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication. J. Virol. 1997;71:9608–9617. doi: 10.1128/jvi.71.12.9608-9617.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Muylaert IR, Chambers TJ, Galler R, Rice CM. Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. Virology. 1996;222:159–168. doi: 10.1006/viro.1996.0406. [DOI] [PubMed] [Google Scholar]
  • 25.Muylaert IR, Galler R, Rice CM. Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation. J. Virol. 1997;71:291–298. doi: 10.1128/jvi.71.1.291-298.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Schlesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J. Gen. Virol. 1987;68(Pt 3):853–857. doi: 10.1099/0022-1317-68-3-853. [DOI] [PubMed] [Google Scholar]
  • 27.Falgout B, Bray M, Schlesinger JJ, Lai CJ. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J. Virol. 1990;64:4356–4363. doi: 10.1128/jvi.64.9.4356-4363.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Avirutnan P, et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 2006;193:1078–1088. doi: 10.1086/500949. [DOI] [PubMed] [Google Scholar]
  • 29.Chung KM, et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc. Natl Acad. Sci. USA. 2006;103:19111–19116. doi: 10.1073/pnas.0605668103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Chung KM, et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J. Virol. 2006;80:1340–1351. doi: 10.1128/JVI.80.3.1340-1351.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Grubor-Bauk B, et al. NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice. Sci. Adv. 2019;5:eaax2388. doi: 10.1126/sciadv.aax2388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Tyler KL. Current developments in understanding of West Nile virus central nervous system disease. Curr. Opin. Neurol. 2014;27:342–348. doi: 10.1097/WCO.0000000000000088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Anukumar B, Sapkal GN, Tandale BV, Balasubramanian R, Gangale D. West Nile encephalitis outbreak in Kerala, India, 2011. J. Clin. Virol. 2014;61:152–155. doi: 10.1016/j.jcv.2014.06.003. [DOI] [PubMed] [Google Scholar]
  • 34.Lu Z, et al. Human infection with West Nile Virus, Xinjiang, China, 2011. Emerg. Infect. Dis. 2014;20:1421–1423. doi: 10.3201/eid2008.131433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Cao L, et al. Detection of West Nile virus infection in viral encephalitis cases, China. Vector Borne Zoonotic Dis. 2019;19:45–50. doi: 10.1089/vbz.2018.2275. [DOI] [PubMed] [Google Scholar]
  • 36.Lobigs M, Diamond MS. Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev. Vaccines. 2012;11:177–187. doi: 10.1586/erv.11.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Bosco-Lauth A, Mason G, Bowen R. Pathogenesis of Japanese encephalitis virus infection in a golden hamster model and evaluation of flavivirus cross-protective immunity. Am. J. Trop. Med. Hyg. 2011;84:727–732. doi: 10.4269/ajtmh.2011.11-0012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lobigs M, Larena M, Alsharifi M, Lee E, Pavy M. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J. Virol. 2009;83:2436–2445. doi: 10.1128/JVI.02273-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Goverdhan MK, Kulkarni AB, Gupta AK, Tupe CD, Rodrigues JJ. Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques. Acta Virol. 1992;36:277–283. [PubMed] [Google Scholar]
  • 40.Tesh RB, Travassos da Rosa AP, Guzman H, Araujo TP, Xiao SY. Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg. Infect. Dis. 2002;8:245–251. doi: 10.3201/eid0803.010238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Takasaki T, et al. Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice. Vaccine. 2003;21:4514–4518. doi: 10.1016/s0264-410x(03)00507-3. [DOI] [PubMed] [Google Scholar]
  • 42.Tang F, et al. Failure of Japanese encephalitis vaccine and infection in inducing neutralizing antibodies against West Nile virus, People’s Republic of China. Am. J. Trop. Med. Hyg. 2008;78:999–1001. [PubMed] [Google Scholar]
  • 43.Yamshchikov G, et al. The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus. Vaccine. 2005;23:4785–4792. doi: 10.1016/j.vaccine.2005.04.036. [DOI] [PubMed] [Google Scholar]
  • 44.Kanesa-Thasan N, Putnak JR, Mangiafico JA, Saluzzo JE, Ludwig GV. Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. Am. J. Trop. Med. Hyg. 2002;66:115–116. doi: 10.4269/ajtmh.2002.66.115. [DOI] [PubMed] [Google Scholar]
  • 45.Petrovsky N, et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J. Virol. 2013;87:10324–10333. doi: 10.1128/JVI.00480-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Zhang HL, et al. Generation and characterization of West Nile pseudo-infectious reporter virus for antiviral screening. Antivir. Res. 2017;141:38–47. doi: 10.1016/j.antiviral.2017.02.006. [DOI] [PubMed] [Google Scholar]
  • 47.Li XD, et al. Recovery of a chemically synthesized Japanese encephalitis virus reveals two critical adaptive mutations in NS2B and NS4A. J. Gen. Virol. 2014;95:806–815. doi: 10.1099/vir.0.061838-0. [DOI] [PubMed] [Google Scholar]
  • 48.Zhang PT, et al. Generation of a recombinant West Nile virus stably expressing the Gaussia luciferase for neutralization assay. Virus Res. 2016;211:17–24. doi: 10.1016/j.virusres.2015.09.015. [DOI] [PubMed] [Google Scholar]
  • 49.Shi PY, Tilgner M, Lo MK, Kent KA, Bernard KA. Infectious cDNA clone of the epidemic west nile virus from New York City. J. Virol. 2002;76:5847–5856. doi: 10.1128/JVI.76.12.5847-5856.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Zhang YN, et al. Infectious chikungunya virus (CHIKV) with a complete capsid deletion: a new approach for a CHIKV vaccine. J. Virol. 2019;93:e00504–e00519. doi: 10.1128/JVI.00504-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zou G, et al. Exclusion of West Nile virus superinfection through RNA replication. J. Virol. 2009;83:11765–11776. doi: 10.1128/JVI.01205-09. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information (525.3KB, pdf)
Reporting Summary (2MB, pdf)

Data Availability Statement

All data to understand and assess the conclusions of this study are available in this published article. The raw data that support the findings of this study are available from the corresponding author upon reasonable request.

Articles from NPJ Vaccines are provided here courtesy of Nature Publishing Group

RESOURCES